GASTRIC CANCER

This early-stage study tested an experimental drug called BLU-222 in 50 people with advanced solid tumors (like breast, ovarian, or stomach cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The st…

This early-phase study tested a new drug (PF-07265028) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, stomach, and head/neck cancers. The goal was to find the safest dose and see if the drug shrinks tumors. The study was stopped early, and…

This study tested a new drug called OC-001, given alone or with an immunotherapy drug (Avelumab), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The study was stopped early and involved 73 participants with v…

This early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…

This study tested a drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to other treatments. The goal was to see if the drug could shrink tumors. However, the trial was stopped earl…

This study tested a new drug (DKN-01) combined with an immunotherapy (tislelizumab) and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that could not be removed by surgery. The trial aimed to see if the combination was safe and could slow cancer…

This study tested a combination of chemotherapy drugs for people with stomach cancer that has spread to the lining of the belly. The drugs were given directly into the belly and through a vein, along with oral medication. The goal was to see if this approach could help patients l…

This early-stage study tested a new drug called AUR106 in 21 adults with advanced solid tumors like lung, stomach, bladder, kidney, colon, or esophageal cancer that had come back or spread. The main goal was to find the safest dose and understand how the drug works in the body. T…

This early-stage trial tested a new drug called SAR443216 in 44 adults with advanced HER2-positive cancers (like breast, lung, or stomach cancer) that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was termina…

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…

This study tested a new drug called TAK-500, given alone or with another drug (pembrolizumab), in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early…

This study aimed to find genetic and lifestyle reasons why Hispanic people in South Texas may develop stomach cancer more often. Researchers compared DNA from tumor samples and surveyed patients about diet, infections, and other exposures. The study was stopped early, so results …